vTv Therapeutics Inc. Net Income Loss

• vTv Therapeutics Inc. showed a decrease of -46.1% in Net Income Loss from 2024 to 2025.
• This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), vTv Therapeutics Inc.'s Net Income Loss has grown by 44.0%.
• Historical annual values: Fiscal year 2025: -$26.97 million | Fiscal year 2024: -$18.46 million | Fiscal year 2023: -$20.25 million | Fiscal year 2022: -$19.16 million | Fiscal year 2021: -$12.99 million | Fiscal year 2020: -$8.50 million | Fiscal year 2019: -$13.04 million | Fiscal year 2018: -$7.91 million | Fiscal year 2017: -$16.14 million | Fiscal year 2016: -$16.35 million | Fiscal year 2015: -$27.50 million | Fiscal year 2014: -$36.10 million | Fiscal year 2013: -$48.20 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026